ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the usage of the “at-the market” equity of its offering program.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti may issue and promote from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares were sold at prevailing market rates averaging US$1.0747 a share. No securities had been offered throughout the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will deliver the Company with additional freedom in its continuous review process to explore and evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical evidence of safety as well as efficacy for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which are not statements of historical or current fact constitute “forward looking information” to the meaning of Canadian securities laws as well as “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, as well as other unknown variables that may cause the particular results of Acasti to be materially different from historical outcomes and as a result of any later results expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the day of this press release. Forward-looking claims in that press release include, but are not confined to, statements or information concerning Acasti’s strategy, succeeding operations and its review of strategic options.
The forward-looking claims found in this specific press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor area of Acasti’s site at www.acastipharma.com. All forward looking assertions in this press release are produced as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward looking statements whether as a result of information which is new, future events or perhaps otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to risks and assumptions and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the use